Hainan Poly Pharm Co Ltd - Asset Resilience Ratio
Hainan Poly Pharm Co Ltd (300630) has an Asset Resilience Ratio of 2.33% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Hainan Poly Pharm Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2022)
This chart shows how Hainan Poly Pharm Co Ltd's Asset Resilience Ratio has changed over time. See 300630 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Hainan Poly Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Hainan Poly Pharm Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥146.93 Million | 2.33% |
| Total Liquid Assets | CN¥146.93 Million | 2.33% |
Asset Resilience Insights
- Limited Liquidity: Hainan Poly Pharm Co Ltd maintains only 2.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Poly Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hainan Poly Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Krka d. d
WAR:KRK |
Drug Manufacturers - Specialty & Generic | 11.18% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263 |
Drug Manufacturers - Specialty & Generic | 6.08% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Hainan Poly Pharm Co Ltd (2020–2022)
The table below shows the annual Asset Resilience Ratio data for Hainan Poly Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.01% | CN¥455.91K ≈ $66.71K |
CN¥5.96 Billion ≈ $871.99 Million |
-1.51pp |
| 2021-12-31 | 1.51% | CN¥70.55 Million ≈ $10.32 Million |
CN¥4.66 Billion ≈ $682.23 Million |
+1.50pp |
| 2020-12-31 | 0.02% | CN¥550.35K ≈ $80.53K |
CN¥3.06 Billion ≈ $447.19 Million |
-- |
About Hainan Poly Pharm Co Ltd
Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more